This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Lung Cancer Therapeutics Market

Market Insights on Lung Cancer Therapeutics covering sales outlook, demand forecast & up-to-date key trends

Lung Cancer Therapeutics Market By Cancer Cell Type, Molecule Type, Mode of Administration, Type & Region - Forecast 2022-2032

Lung Cancer Therapeutics Market Overview (2022-2032)

[250 Pages Report] The global lung cancer therapeutics market share is projected to reach US$ 48,725.9 Mn by 2026, exhibiting a CAGR of 13.4% in the forecast period.

Lung cancer diagnoses have increased as a result of increased cancer awareness in both advanced and emerging economies, as well as the introduction of new medical diagnostic equipment and improved treatments, propelling the lung cancer therapeutics market forward.

This, along with increased spending in research and innovation by leading players, is fueling the demand for lung cancer therapeutics. The shift in the market is mostly due to a higher focus on research projects as a result of the rising incidence of lung cancer.

Report Attribute

Details

Expected Market Value (2026)

US$ 48,725.9 Mn

Projected Growth Rate (2022-2032)

13.4% CAGR

The worldwide lung cancer therapeutics market is predicted to grow at a high rate as the incidence of lung cancer rises. The global lung cancer therapeutics market is being driven by a growing demand for tailored therapy, the availability of highly effective medications, an increase in the elderly population, and an increase in the prevalence of unhealthy lifestyles.

The introduction of nanomedicine to treat lung cancer and the growing number of approvals in the lung cancer treatments market are driving the demand for lung cancer therapeutics.

In addition to rising regulatory approvals and the acceptance of modern treatments in Europe, the lung cancer therapeutics market is predicted to develop.

In growing economies such as China and India, however, the surge in lung disease prevalence and the dominance of chemotherapy are driving the growth of the lung cancer therapeutics market. Advanced immunotherapies and tailored medicines are becoming more expensive in countries like Japan, thus limiting the demand for lung cancer therapeutics.

Customize this Report

Let us know your requirement to get
100% FREE customization

What are the Key Contributors to the Demand for Lung Cancer Therapeutics?

Lung cancer is a malignant tumor characterized by the uncontrolled growth of cell tissues in the lung. It is the second most commonly diagnosed and has the highest mortality rate of all cancers in both men and women. Thus, with the rise in the incidence rate of lung cancer, the demand for lung cancer therapeutics is also expected to grow during the study period.

Increasing incidences of lung cancer due to the rising smoking population is one of the major factors driving the growth of the lung cancer therapeutics market. The risk of lung cancer is tenfold higher in smokers as compared to non-smokers.

In addition, the launch of premium-priced drugs, new innovative radiation therapies coupled with rising incidences of NSCLC is the major driving factors for the growth of the lung cancer therapeutics market. However, the generalization of the major drugs might restrict the demand for lung cancer therapeutics.

How is the Lung Cancer Therapeutics Market Segmented?

Based on the cancer cell types, lung cancer is broadly segmented as small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC segment accounts for approximately 80 to 90% of all lung cancers. 

Based on the cell shape and size, NSCLC is further divided into three subtypes they are adenocarcinoma, large-cell carcinoma, and squamous cell carcinoma. These NSCLCs are primarily treated with surgeries. At the same time, chemotherapy is increasingly used for both pre-operative and post-operative treatment of patients. 

The treatment options available for the NSCLC include surgery, radiation therapy, and chemotherapy. The top five global brands that are commercially available in the market are Avastin, Tarceva, Alimta, Gemzar, and Taxotere. Thus, all the above mentioned factors collectively drive the growth of the global lung cancer therapeutics market.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Which Region Dominates the Lung Cancer Therapeutics Market?

Geographically, North America and Europe dominate the global lung cancer therapeutics market. According to Lung Disease Research Funding, approximately 75,000 people in the U.S. die because of lung injury every year.

The United States is the largest market for NSCLC owing to the high incidence rate rise in the aging population. In addition, with the advent of new treatment therapies such as targeted drug therapy, stereotactic are aiding the growth of lung cancer therapeutics market share.

Europe accounts for the highest demand for lung cancer therapeutics after North America. At the same time, Asia-Pacific countries such as India and China, South East Asia are the emerging regions for the global lung cancer therapeutics market due to the high prevalence of this disease coupled with increasing healthcare awareness.

How is the Competitive Landscape in the Lung Cancer Therapeutics Market?

Players are adopting various strategies to expand their product portfolio and increase their geographical presence for demand for lung cancer therapeutics. Some of the key strategies used by players in the global lung cancer therapeutics market include product innovation, partnerships and alliances, and mergers.

The prominent leading players of driving the lung cancer therapeutics market share include AstraZeneca Lc, Eli Lilly, and Company, GlaxoSmithKline, Hoffman-La Roche, Boehringer Ingelheim GmbH, Pfizer Inc., Sanofi-Aventis, among others.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Scope Of Report

Report Attribute

Details

Growth rate

CAGR of 13.4% from 2022 to 2030

Base year for estimation

2021

Historical data

2015 - 2020

Forecast period

2022 - 2032

Quantitative units

Revenue in USD Million, volume in kilotons, and CAGR from 2022 to 2032

Report coverage

Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis,

Segments covered

Product, application, region

Regional scope

North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia and New Zealand

Country scope

U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa

Key companies profiled

AstrazenecaPlc, Sanofi-Aventis., GlaxoSmitKline, Eli Lilly and Company,  BoehringerIngelheim GmbH, Pfizer Inc., Hoffman-La Roche

Customization scope

Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs.

Key Segments

By Cancer Cell Type:

  • Small Lung Cancer
  • Non-Small Lung Cancer (NSLC)

By Molecule Type:

  • Biologics
  • Small Molecules

By Mode of Administration:

  • Injectable
  • Oral

By Type:

  • AML
  • CML
  • ALL
  • CLL

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • MEA

Frequently Asked Questions

Targeted therapy is the leading segment in the lung cancer therapeutics market.

Demand for lung cancer therapeutics is projected to advance at a CAGR of 13.4% during the forecast period.

North America has the highest lung cancer therapeutics market share.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity 

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. Value Chain Analysis

        3.5.1. Profit Margin Analysis

        3.5.2. Service Providers

    3.6. PESTLE and Porter's Analysis

    3.7. Regulatory Landscape

        3.7.1. By Key Regions

        3.7.2. By Key Countries

    3.8. Regional Parent Market Outlook

4. Global Lung Cancer Therapeutics Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Lung Cancer Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Treatment Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Treatment Type, 2017-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Treatment Type, 2022-2032

        5.3.1. Chemotherapy

        5.3.2. Targeted Therapy

        5.3.3. Radiotherapy

        5.3.4. Biological Therapy

    5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2017-2021

    5.5. Absolute $ Opportunity Analysis By Treatment Type, 2022-2032 Deep-dive segmentation will be available in the sample on request

6. Global Lung Cancer Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Disease Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Disease Type, 2017-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease Type, 2022-2032

        6.3.1. Non-small Cell Lung Cancer (NSCLC)

        6.3.2. Small Cell Lung Cancer (SCLC)

    6.4. Y-o-Y Growth Trend Analysis By Disease Type, 2017-2021

    6.5. Absolute $ Opportunity Analysis By Disease Type, 2022-2032 Deep-dive segmentation will be available in the sample on request

7. Global Lung Cancer Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2017-2021

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2022-2032

        7.3.1. Immunosuppressant

        7.3.2. Monoclonal Antibodies

        7.3.3. Tyrosine Kinase

        7.3.4. Epidermal Growth Factors Receptors

        7.3.5. Topoisomerase Inhibitors

        7.3.6. Others 

    7.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017-2021

    7.5. Absolute $ Opportunity Analysis By Drug Class, 2022-2032 Deep-dive segmentation will be available in the sample on request

8. Global Lung Cancer Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration 

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration , 2017-2021

    8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration , 2022-2032

        8.3.1. Oral

        8.3.2. Injectable

    8.4. Y-o-Y Growth Trend Analysis By Route of Administration , 2017-2021

    8.5. Absolute $ Opportunity Analysis By Route of Administration , 2022-2032 Deep-dive segmentation will be available in the sample on request

9. Global Lung Cancer Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

    9.1. Introduction / Key Findings

    9.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021

    9.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032

        9.3.1. Hospital

        9.3.2. Specialty Clinics

        9.3.3. Clinical Research Institutes

        9.3.4. Home Care Settings

        9.3.5. Ambulatory Surgical Centers

    9.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021

    9.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032 Deep-dive segmentation will be available in the sample on request

10. Global Lung Cancer Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    10.1. Introduction

    10.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

    10.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. East Asia

        10.3.5. South Asia & Pacific

        10.3.6. MEA

    10.4. Market Attractiveness Analysis By Region

11. North America Lung Cancer Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. U.S.

            11.2.1.2. Canada

        11.2.2. By Treatment Type

        11.2.3. By Disease Type

        11.2.4. By Drug Class

        11.2.5. By Route of Administration 

        11.2.6. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment Type

        11.3.3. By Disease Type

        11.3.4. By Drug Class

        11.3.5. By Route of Administration 

        11.3.6. By Distribution Channel

    11.4. Key Takeaways

12. Latin America Lung Cancer Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. Mexico

            12.2.1.2. Brazil

            12.2.1.3. Rest of Latin America

        12.2.2. By Treatment Type

        12.2.3. By Disease Type

        12.2.4. By Drug Class

        12.2.5. By Route of Administration 

        12.2.6. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment Type

        12.3.3. By Disease Type

        12.3.4. By Drug Class

        12.3.5. By Route of Administration 

        12.3.6. By Distribution Channel

    12.4. Key Takeaways

13. Europe Lung Cancer Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. Germany

            13.2.1.2. Italy

            13.2.1.3. France

            13.2.1.4. U.K.

            13.2.1.5. Spain

            13.2.1.6. BENELUX

            13.2.1.7. Russia

            13.2.1.8. Rest of Europe

        13.2.2. By Treatment Type

        13.2.3. By Disease Type

        13.2.4. By Drug Class

        13.2.5. By Route of Administration 

        13.2.6. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Treatment Type

        13.3.3. By Disease Type

        13.3.4. By Drug Class

        13.3.5. By Route of Administration 

        13.3.6. By Distribution Channel

    13.4. Key Takeaways

14. East Asia Lung Cancer Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Treatment Type

        14.2.3. By Disease Type

        14.2.4. By Drug Class

        14.2.5. By Route of Administration 

        14.2.6. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Treatment Type

        14.3.3. By Disease Type

        14.3.4. By Drug Class

        14.3.5. By Route of Administration 

        14.3.6. By Distribution Channel

    14.4. Key Takeaways

15. South Asia & Pacific Lung Cancer Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    15.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    15.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        15.2.1. By Country

            15.2.1.1. India

            15.2.1.2. ASEAN

            15.2.1.3. Australia and New Zealand

            15.2.1.4. Rest of South Asia & Pacific

        15.2.2. By Treatment Type

        15.2.3. By Disease Type

        15.2.4. By Drug Class

        15.2.5. By Route of Administration 

        15.2.6. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Treatment Type

        15.3.3. By Disease Type

        15.3.4. By Drug Class

        15.3.5. By Route of Administration 

        15.3.6. By Distribution Channel

    15.4. Key Takeaways

16. MEA Lung Cancer Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    16.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    16.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        16.2.1. By Country

            16.2.1.1. GCC Countries

            16.2.1.2. Turkey

            16.2.1.3. South Africa

            16.2.1.4. Rest of MEA

        16.2.2. By Treatment Type

        16.2.3. By Disease Type

        16.2.4. By Drug Class

        16.2.5. By Route of Administration 

        16.2.6. By Distribution Channel

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Treatment Type

        16.3.3. By Disease Type

        16.3.4. By Drug Class

        16.3.5. By Route of Administration 

        16.3.6. By Distribution Channel

    16.4. Key Takeaways

17. Key Countries Lung Cancer Therapeutics Market Analysis

    17.1. U.S.

        17.1.1. Pricing Analysis

        17.1.2. Market Share Analysis, 2021

            17.1.2.1. By Treatment Type

            17.1.2.2. By Disease Type

            17.1.2.3. By Drug Class

            17.1.2.4. By Route of Administration 

            17.1.2.5. By Distribution Channel

    17.2. Canada

        17.2.1. Pricing Analysis

        17.2.2. Market Share Analysis, 2021

            17.2.2.1. By Treatment Type

            17.2.2.2. By Disease Type

            17.2.2.3. By Drug Class

            17.2.2.4. By Route of Administration 

            17.2.2.5. By Distribution Channel

    17.3. Mexico

        17.3.1. Pricing Analysis

        17.3.2. Market Share Analysis, 2021

            17.3.2.1. By Treatment Type

            17.3.2.2. By Disease Type

            17.3.2.3. By Drug Class

            17.3.2.4. By Route of Administration 

            17.3.2.5. By Distribution Channel

    17.4. Brazil

        17.4.1. Pricing Analysis

        17.4.2. Market Share Analysis, 2021

            17.4.2.1. By Treatment Type

            17.4.2.2. By Disease Type

            17.4.2.3. By Drug Class

            17.4.2.4. By Route of Administration 

            17.4.2.5. By Distribution Channel

    17.5. Germany

        17.5.1. Pricing Analysis

        17.5.2. Market Share Analysis, 2021

            17.5.2.1. By Treatment Type

            17.5.2.2. By Disease Type

            17.5.2.3. By Drug Class

            17.5.2.4. By Route of Administration 

            17.5.2.5. By Distribution Channel

    17.6. Italy

        17.6.1. Pricing Analysis

        17.6.2. Market Share Analysis, 2021

            17.6.2.1. By Treatment Type

            17.6.2.2. By Disease Type

            17.6.2.3. By Drug Class

            17.6.2.4. By Route of Administration 

            17.6.2.5. By Distribution Channel

    17.7. France

        17.7.1. Pricing Analysis

        17.7.2. Market Share Analysis, 2021

            17.7.2.1. By Treatment Type

            17.7.2.2. By Disease Type

            17.7.2.3. By Drug Class

            17.7.2.4. By Route of Administration 

            17.7.2.5. By Distribution Channel

    17.8. U.K.

        17.8.1. Pricing Analysis

        17.8.2. Market Share Analysis, 2021

            17.8.2.1. By Treatment Type

            17.8.2.2. By Disease Type

            17.8.2.3. By Drug Class

            17.8.2.4. By Route of Administration 

            17.8.2.5. By Distribution Channel

    17.9. Spain

        17.9.1. Pricing Analysis

        17.9.2. Market Share Analysis, 2021

            17.9.2.1. By Treatment Type

            17.9.2.2. By Disease Type

            17.9.2.3. By Drug Class

            17.9.2.4. By Route of Administration 

            17.9.2.5. By Distribution Channel

    17.10. BENELUX

        17.10.1. Pricing Analysis

        17.10.2. Market Share Analysis, 2021

            17.10.2.1. By Treatment Type

            17.10.2.2. By Disease Type

            17.10.2.3. By Drug Class

            17.10.2.4. By Route of Administration 

            17.10.2.5. By Distribution Channel

    17.11. Russia

        17.11.1. Pricing Analysis

        17.11.2. Market Share Analysis, 2021

            17.11.2.1. By Treatment Type

            17.11.2.2. By Disease Type

            17.11.2.3. By Drug Class

            17.11.2.4. By Route of Administration 

            17.11.2.5. By Distribution Channel

    17.12. China

        17.12.1. Pricing Analysis

        17.12.2. Market Share Analysis, 2021

            17.12.2.1. By Treatment Type

            17.12.2.2. By Disease Type

            17.12.2.3. By Drug Class

            17.12.2.4. By Route of Administration 

            17.12.2.5. By Distribution Channel

    17.13. Japan

        17.13.1. Pricing Analysis

        17.13.2. Market Share Analysis, 2021

            17.13.2.1. By Treatment Type

            17.13.2.2. By Disease Type

            17.13.2.3. By Drug Class

            17.13.2.4. By Route of Administration 

            17.13.2.5. By Distribution Channel

    17.14. South Korea

        17.14.1. Pricing Analysis

        17.14.2. Market Share Analysis, 2021

            17.14.2.1. By Treatment Type

            17.14.2.2. By Disease Type

            17.14.2.3. By Drug Class

            17.14.2.4. By Route of Administration 

            17.14.2.5. By Distribution Channel

    17.15. India

        17.15.1. Pricing Analysis

        17.15.2. Market Share Analysis, 2021

            17.15.2.1. By Treatment Type

            17.15.2.2. By Disease Type

            17.15.2.3. By Drug Class

            17.15.2.4. By Route of Administration 

            17.15.2.5. By Distribution Channel

    17.16. ASEAN

        17.16.1. Pricing Analysis

        17.16.2. Market Share Analysis, 2021

            17.16.2.1. By Treatment Type

            17.16.2.2. By Disease Type

            17.16.2.3. By Drug Class

            17.16.2.4. By Route of Administration 

            17.16.2.5. By Distribution Channel

    17.17. Australia and New Zealand

        17.17.1. Pricing Analysis

        17.17.2. Market Share Analysis, 2021

            17.17.2.1. By Treatment Type

            17.17.2.2. By Disease Type

            17.17.2.3. By Drug Class

            17.17.2.4. By Route of Administration 

            17.17.2.5. By Distribution Channel

    17.18. GCC Countries

        17.18.1. Pricing Analysis

        17.18.2. Market Share Analysis, 2021

            17.18.2.1. By Treatment Type

            17.18.2.2. By Disease Type

            17.18.2.3. By Drug Class

            17.18.2.4. By Route of Administration 

            17.18.2.5. By Distribution Channel

    17.19. Turkey

        17.19.1. Pricing Analysis

        17.19.2. Market Share Analysis, 2021

            17.19.2.1. By Treatment Type

            17.19.2.2. By Disease Type

            17.19.2.3. By Drug Class

            17.19.2.4. By Route of Administration 

            17.19.2.5. By Distribution Channel

    17.20. South Africa

        17.20.1. Pricing Analysis

        17.20.2. Market Share Analysis, 2021

            17.20.2.1. By Treatment Type

            17.20.2.2. By Disease Type

            17.20.2.3. By Drug Class

            17.20.2.4. By Route of Administration 

            17.20.2.5. By Distribution Channel

18. Market Structure Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Market Share Analysis of Top Players

        18.3.1. By Regional

        18.3.2. By Treatment Type

        18.3.3. By Disease Type

        18.3.4. By Drug Class

        18.3.5. By Route of Administration 

        18.3.6. By Distribution Channel

19. Competition Analysis

    19.1. Competition Deep Dive

        19.1.1. F. Hoffmann-La Roche Ltd

            19.1.1.1. Overview

            19.1.1.2. Product Portfolio

            19.1.1.3. Profitability by Market Segments

            19.1.1.4. Sales Footprint

            19.1.1.5. Strategy Overview

                19.1.1.5.1. Marketing Strategy

                19.1.1.5.2. Product Strategy

                19.1.1.5.3. Channel Strategy

        19.1.2. GlaxoSmithKline plc.

            19.1.2.1. Overview

            19.1.2.2. Product Portfolio

            19.1.2.3. Profitability by Market Segments

            19.1.2.4. Sales Footprint

            19.1.2.5. Strategy Overview

                19.1.2.5.1. Marketing Strategy

                19.1.2.5.2. Product Strategy

                19.1.2.5.3. Channel Strategy

        19.1.3. Merck & Co.

            19.1.3.1. Overview

            19.1.3.2. Product Portfolio

            19.1.3.3. Profitability by Market Segments

            19.1.3.4. Sales Footprint

            19.1.3.5. Strategy Overview

                19.1.3.5.1. Marketing Strategy

                19.1.3.5.2. Product Strategy

                19.1.3.5.3. Channel Strategy

        19.1.4. Agennix AG

            19.1.4.1. Overview

            19.1.4.2. Product Portfolio

            19.1.4.3. Profitability by Market Segments

            19.1.4.4. Sales Footprint

            19.1.4.5. Strategy Overview

                19.1.4.5.1. Marketing Strategy

                19.1.4.5.2. Product Strategy

                19.1.4.5.3. Channel Strategy

        19.1.5. Boehringer Ingelheim GmbH

            19.1.5.1. Overview

            19.1.5.2. Product Portfolio

            19.1.5.3. Profitability by Market Segments

            19.1.5.4. Sales Footprint

            19.1.5.5. Strategy Overview

                19.1.5.5.1. Marketing Strategy

                19.1.5.5.2. Product Strategy

                19.1.5.5.3. Channel Strategy

        19.1.6. Sanofi-Aventis

            19.1.6.1. Overview

            19.1.6.2. Product Portfolio

            19.1.6.3. Profitability by Market Segments

            19.1.6.4. Sales Footprint

            19.1.6.5. Strategy Overview

                19.1.6.5.1. Marketing Strategy

                19.1.6.5.2. Product Strategy

                19.1.6.5.3. Channel Strategy

        19.1.7. Eli Lilly and Company

            19.1.7.1. Overview

            19.1.7.2. Product Portfolio

            19.1.7.3. Profitability by Market Segments

            19.1.7.4. Sales Footprint

            19.1.7.5. Strategy Overview

                19.1.7.5.1. Marketing Strategy

                19.1.7.5.2. Product Strategy

                19.1.7.5.3. Channel Strategy

        19.1.8. Celgene Corporation

            19.1.8.1. Overview

            19.1.8.2. Product Portfolio

            19.1.8.3. Profitability by Market Segments

            19.1.8.4. Sales Footprint

            19.1.8.5. Strategy Overview

                19.1.8.5.1. Marketing Strategy

                19.1.8.5.2. Product Strategy

                19.1.8.5.3. Channel Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Region, 2017-2032

Table 2: Global Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Treatment Type, 2017-2032

Table 3: Global Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Disease Type, 2017-2032

Table 4: Global Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 5: Global Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Route of Administration , 2017-2032

Table 6: Global Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 7: North America Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 8: North America Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Treatment Type, 2017-2032

Table 9: North America Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Disease Type, 2017-2032

Table 10: North America Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 11: North America Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Route of Administration , 2017-2032

Table 12: North America Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 13: Latin America Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 14: Latin America Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Treatment Type, 2017-2032

Table 15: Latin America Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Disease Type, 2017-2032

Table 16: Latin America Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 17: Latin America Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Route of Administration , 2017-2032

Table 18: Latin America Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 19: Europe Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 20: Europe Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Treatment Type, 2017-2032

Table 21: Europe Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Disease Type, 2017-2032

Table 22: Europe Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 23: Europe Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Route of Administration , 2017-2032

Table 24: Europe Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 25: East Asia Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 26: East Asia Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Treatment Type, 2017-2032

Table 27: East Asia Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Disease Type, 2017-2032

Table 28: East Asia Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 29: East Asia Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Route of Administration , 2017-2032

Table 30: East Asia Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 31: South Asia & Pacific Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 32: South Asia & Pacific Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Treatment Type, 2017-2032

Table 33: South Asia & Pacific Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Disease Type, 2017-2032

Table 34: South Asia & Pacific Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 35: South Asia & Pacific Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Route of Administration , 2017-2032

Table 36: South Asia & Pacific Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 37: MEA Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 38: MEA Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Treatment Type, 2017-2032

Table 39: MEA Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Disease Type, 2017-2032

Table 40: MEA Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 41: MEA Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Route of Administration , 2017-2032

Table 42: MEA Lung Cancer Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Lung Cancer Therapeutics Market Value (US$ Mn) by Treatment Type, 2022-2032

Figure 2: Global Lung Cancer Therapeutics Market Value (US$ Mn) by Disease Type, 2022-2032

Figure 3: Global Lung Cancer Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 4: Global Lung Cancer Therapeutics Market Value (US$ Mn) by Route of Administration , 2022-2032

Figure 5: Global Lung Cancer Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 6: Global Lung Cancer Therapeutics Market Value (US$ Mn) by Region, 2022-2032

Figure 7: Global Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Region, 2017-2032

Figure 8: Global Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 9: Global Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 10: Global Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Treatment Type, 2017-2032

Figure 11: Global Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Treatment Type, 2022-2032

Figure 12: Global Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Treatment Type, 2022-2032

Figure 13: Global Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Disease Type, 2017-2032

Figure 14: Global Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032

Figure 15: Global Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032

Figure 16: Global Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 17: Global Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 18: Global Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 19: Global Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Route of Administration , 2017-2032

Figure 20: Global Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Route of Administration , 2022-2032

Figure 21: Global Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Route of Administration , 2022-2032

Figure 22: Global Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 23: Global Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 24: Global Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 25: Global Lung Cancer Therapeutics Market Attractiveness by Treatment Type, 2022-2032

Figure 26: Global Lung Cancer Therapeutics Market Attractiveness by Disease Type, 2022-2032

Figure 27: Global Lung Cancer Therapeutics Market Attractiveness by Drug Class, 2022-2032

Figure 28: Global Lung Cancer Therapeutics Market Attractiveness by Route of Administration , 2022-2032

Figure 29: Global Lung Cancer Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 30: Global Lung Cancer Therapeutics Market Attractiveness by Region, 2022-2032

Figure 31: North America Lung Cancer Therapeutics Market Value (US$ Mn) by Treatment Type, 2022-2032

Figure 32: North America Lung Cancer Therapeutics Market Value (US$ Mn) by Disease Type, 2022-2032

Figure 33: North America Lung Cancer Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 34: North America Lung Cancer Therapeutics Market Value (US$ Mn) by Route of Administration , 2022-2032

Figure 35: North America Lung Cancer Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 36: North America Lung Cancer Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 37: North America Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 38: North America Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 39: North America Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 40: North America Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Treatment Type, 2017-2032

Figure 41: North America Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Treatment Type, 2022-2032

Figure 42: North America Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Treatment Type, 2022-2032

Figure 43: North America Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Disease Type, 2017-2032

Figure 44: North America Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032

Figure 45: North America Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032

Figure 46: North America Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 47: North America Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 48: North America Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 49: North America Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Route of Administration , 2017-2032

Figure 50: North America Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Route of Administration , 2022-2032

Figure 51: North America Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Route of Administration , 2022-2032

Figure 52: North America Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 53: North America Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 54: North America Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 55: North America Lung Cancer Therapeutics Market Attractiveness by Treatment Type, 2022-2032

Figure 56: North America Lung Cancer Therapeutics Market Attractiveness by Disease Type, 2022-2032

Figure 57: North America Lung Cancer Therapeutics Market Attractiveness by Drug Class, 2022-2032

Figure 58: North America Lung Cancer Therapeutics Market Attractiveness by Route of Administration , 2022-2032

Figure 59: North America Lung Cancer Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 60: North America Lung Cancer Therapeutics Market Attractiveness by Country, 2022-2032

Figure 61: Latin America Lung Cancer Therapeutics Market Value (US$ Mn) by Treatment Type, 2022-2032

Figure 62: Latin America Lung Cancer Therapeutics Market Value (US$ Mn) by Disease Type, 2022-2032

Figure 63: Latin America Lung Cancer Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 64: Latin America Lung Cancer Therapeutics Market Value (US$ Mn) by Route of Administration , 2022-2032

Figure 65: Latin America Lung Cancer Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 66: Latin America Lung Cancer Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 67: Latin America Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 68: Latin America Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 69: Latin America Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 70: Latin America Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Treatment Type, 2017-2032

Figure 71: Latin America Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Treatment Type, 2022-2032

Figure 72: Latin America Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Treatment Type, 2022-2032

Figure 73: Latin America Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Disease Type, 2017-2032

Figure 74: Latin America Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032

Figure 75: Latin America Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032

Figure 76: Latin America Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 77: Latin America Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 78: Latin America Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 79: Latin America Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Route of Administration , 2017-2032

Figure 80: Latin America Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Route of Administration , 2022-2032

Figure 81: Latin America Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Route of Administration , 2022-2032

Figure 82: Latin America Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 83: Latin America Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 84: Latin America Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 85: Latin America Lung Cancer Therapeutics Market Attractiveness by Treatment Type, 2022-2032

Figure 86: Latin America Lung Cancer Therapeutics Market Attractiveness by Disease Type, 2022-2032

Figure 87: Latin America Lung Cancer Therapeutics Market Attractiveness by Drug Class, 2022-2032

Figure 88: Latin America Lung Cancer Therapeutics Market Attractiveness by Route of Administration , 2022-2032

Figure 89: Latin America Lung Cancer Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 90: Latin America Lung Cancer Therapeutics Market Attractiveness by Country, 2022-2032

Figure 91: Europe Lung Cancer Therapeutics Market Value (US$ Mn) by Treatment Type, 2022-2032

Figure 92: Europe Lung Cancer Therapeutics Market Value (US$ Mn) by Disease Type, 2022-2032

Figure 93: Europe Lung Cancer Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 94: Europe Lung Cancer Therapeutics Market Value (US$ Mn) by Route of Administration , 2022-2032

Figure 95: Europe Lung Cancer Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 96: Europe Lung Cancer Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 97: Europe Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 98: Europe Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 99: Europe Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 100: Europe Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Treatment Type, 2017-2032

Figure 101: Europe Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Treatment Type, 2022-2032

Figure 102: Europe Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Treatment Type, 2022-2032

Figure 103: Europe Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Disease Type, 2017-2032

Figure 104: Europe Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032

Figure 105: Europe Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032

Figure 106: Europe Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 107: Europe Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 108: Europe Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 109: Europe Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Route of Administration , 2017-2032

Figure 110: Europe Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Route of Administration , 2022-2032

Figure 111: Europe Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Route of Administration , 2022-2032

Figure 112: Europe Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 113: Europe Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 114: Europe Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 115: Europe Lung Cancer Therapeutics Market Attractiveness by Treatment Type, 2022-2032

Figure 116: Europe Lung Cancer Therapeutics Market Attractiveness by Disease Type, 2022-2032

Figure 117: Europe Lung Cancer Therapeutics Market Attractiveness by Drug Class, 2022-2032

Figure 118: Europe Lung Cancer Therapeutics Market Attractiveness by Route of Administration , 2022-2032

Figure 119: Europe Lung Cancer Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 120: Europe Lung Cancer Therapeutics Market Attractiveness by Country, 2022-2032

Figure 121: East Asia Lung Cancer Therapeutics Market Value (US$ Mn) by Treatment Type, 2022-2032

Figure 122: East Asia Lung Cancer Therapeutics Market Value (US$ Mn) by Disease Type, 2022-2032

Figure 123: East Asia Lung Cancer Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 124: East Asia Lung Cancer Therapeutics Market Value (US$ Mn) by Route of Administration , 2022-2032

Figure 125: East Asia Lung Cancer Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 126: East Asia Lung Cancer Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 127: East Asia Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 128: East Asia Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 129: East Asia Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 130: East Asia Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Treatment Type, 2017-2032

Figure 131: East Asia Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Treatment Type, 2022-2032

Figure 132: East Asia Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Treatment Type, 2022-2032

Figure 133: East Asia Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Disease Type, 2017-2032

Figure 134: East Asia Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032

Figure 135: East Asia Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032

Figure 136: East Asia Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 137: East Asia Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 138: East Asia Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 139: East Asia Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Route of Administration , 2017-2032

Figure 140: East Asia Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Route of Administration , 2022-2032

Figure 141: East Asia Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Route of Administration , 2022-2032

Figure 142: East Asia Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 143: East Asia Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 144: East Asia Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 145: East Asia Lung Cancer Therapeutics Market Attractiveness by Treatment Type, 2022-2032

Figure 146: East Asia Lung Cancer Therapeutics Market Attractiveness by Disease Type, 2022-2032

Figure 147: East Asia Lung Cancer Therapeutics Market Attractiveness by Drug Class, 2022-2032

Figure 148: East Asia Lung Cancer Therapeutics Market Attractiveness by Route of Administration , 2022-2032

Figure 149: East Asia Lung Cancer Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 150: East Asia Lung Cancer Therapeutics Market Attractiveness by Country, 2022-2032

Figure 151: South Asia & Pacific Lung Cancer Therapeutics Market Value (US$ Mn) by Treatment Type, 2022-2032

Figure 152: South Asia & Pacific Lung Cancer Therapeutics Market Value (US$ Mn) by Disease Type, 2022-2032

Figure 153: South Asia & Pacific Lung Cancer Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 154: South Asia & Pacific Lung Cancer Therapeutics Market Value (US$ Mn) by Route of Administration , 2022-2032

Figure 155: South Asia & Pacific Lung Cancer Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 156: South Asia & Pacific Lung Cancer Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 157: South Asia & Pacific Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 158: South Asia & Pacific Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 159: South Asia & Pacific Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 160: South Asia & Pacific Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Treatment Type, 2017-2032

Figure 161: South Asia & Pacific Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Treatment Type, 2022-2032

Figure 162: South Asia & Pacific Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Treatment Type, 2022-2032

Figure 163: South Asia & Pacific Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Disease Type, 2017-2032

Figure 164: South Asia & Pacific Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032

Figure 165: South Asia & Pacific Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032

Figure 166: South Asia & Pacific Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 167: South Asia & Pacific Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 168: South Asia & Pacific Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 169: South Asia & Pacific Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Route of Administration , 2017-2032

Figure 170: South Asia & Pacific Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Route of Administration , 2022-2032

Figure 171: South Asia & Pacific Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Route of Administration , 2022-2032

Figure 172: South Asia & Pacific Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 173: South Asia & Pacific Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 174: South Asia & Pacific Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 175: South Asia & Pacific Lung Cancer Therapeutics Market Attractiveness by Treatment Type, 2022-2032

Figure 176: South Asia & Pacific Lung Cancer Therapeutics Market Attractiveness by Disease Type, 2022-2032

Figure 177: South Asia & Pacific Lung Cancer Therapeutics Market Attractiveness by Drug Class, 2022-2032

Figure 178: South Asia & Pacific Lung Cancer Therapeutics Market Attractiveness by Route of Administration , 2022-2032

Figure 179: South Asia & Pacific Lung Cancer Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 180: South Asia & Pacific Lung Cancer Therapeutics Market Attractiveness by Country, 2022-2032

Figure 181: MEA Lung Cancer Therapeutics Market Value (US$ Mn) by Treatment Type, 2022-2032

Figure 182: MEA Lung Cancer Therapeutics Market Value (US$ Mn) by Disease Type, 2022-2032

Figure 183: MEA Lung Cancer Therapeutics Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 184: MEA Lung Cancer Therapeutics Market Value (US$ Mn) by Route of Administration , 2022-2032

Figure 185: MEA Lung Cancer Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 186: MEA Lung Cancer Therapeutics Market Value (US$ Mn) by Country, 2022-2032

Figure 187: MEA Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 188: MEA Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 189: MEA Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 190: MEA Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Treatment Type, 2017-2032

Figure 191: MEA Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Treatment Type, 2022-2032

Figure 192: MEA Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Treatment Type, 2022-2032

Figure 193: MEA Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Disease Type, 2017-2032

Figure 194: MEA Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032

Figure 195: MEA Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032

Figure 196: MEA Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 197: MEA Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 198: MEA Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 199: MEA Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Route of Administration , 2017-2032

Figure 200: MEA Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Route of Administration , 2022-2032

Figure 201: MEA Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Route of Administration , 2022-2032

Figure 202: MEA Lung Cancer Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 203: MEA Lung Cancer Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 204: MEA Lung Cancer Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 205: MEA Lung Cancer Therapeutics Market Attractiveness by Treatment Type, 2022-2032

Figure 206: MEA Lung Cancer Therapeutics Market Attractiveness by Disease Type, 2022-2032

Figure 207: MEA Lung Cancer Therapeutics Market Attractiveness by Drug Class, 2022-2032

Figure 208: MEA Lung Cancer Therapeutics Market Attractiveness by Route of Administration , 2022-2032

Figure 209: MEA Lung Cancer Therapeutics Market Attractiveness by Distribution Channel, 2022-2032

Figure 210: MEA Lung Cancer Therapeutics Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Autoimmune Disease Therapeutics Market

Published : February 2016

Healthcare

Hepatitis - B Therapeutics Market

Published : February 2016

Healthcare

Peptide Therapeutics Market

Published : February 2022

Healthcare

Leukemia Therapeutics Treatment Market

Published : February 2022

Google translate

Lung Cancer Therapeutics Market